Dustin Boothe, MD
Radiation Oncology · Greeley, CONPI 1700128154
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,178 of the $55,021 with a category attached, or 76.7%. Novartis accounts for 79.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $39,324 and has fallen 61.4% since, to $15,176 in 2025. Among radiation oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $743.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$44K
- GE HealthCare$6K
- Siemens Medical Solutions USA, Inc.$2K
- Bayer$2K
- Telix Pharmaceuticals$590
- Daiichi Sankyo Inc.$92
- plus $505 from 17 others
Across 7 payments — averaging $12,397 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$84K
- Telix Pharmaceuticals$3K
What the payments were for
- Consulting fees$42,17877%
- Speaking & faculty fees$6,15711%
- Travel & lodging$4,5998%
- Food & beverage$2,0884%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 25 | $43,936 |
| GE HealthCare | 5 | $5,855 |
| Siemens Medical Solutions USA, Inc. | 3 | $2,255 |
| Bayer | 4 | $1,787 |
| Telix Pharmaceuticals | 6 | $590 |
| Daiichi Sankyo Inc. | 4 | $92 |
| Progenics Pharmaceuticals, Inc. | 5 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Merck | 2 | $42 |
| Pfizer | 2 | $38 |
| Boston Scientific | 2 | $36 |
| EMD Serono, Inc. | 1 | $35 |
| AstraZeneca | 2 | $34 |
| Varian Medical Systems, Inc. | 1 | $30 |
| Johnson & Johnson | 1 | $23 |
| Novocure Inc. | 2 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Genmab U.S., Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $13 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Varian Treatment$2,000
- PLUVICTO$1,369
- ILLUCCIX$960
- Lutathera$388
- TrueBeam$199
How this compares
$55,021 in reported general payments places this provider in the 95th percentile of 105 radiation oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 15 | $107 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Greeley
- Mark DziemianowiczGreeley$1K
- Peter RossiGlenwood Springs$146K
- Suraj SinghGreely$134K
- Meera PatelAurora$112K
- David RabenAurora$61K
- Kevin ScheweThornton$51K
- Christine FisherAurora$28K
- Thomas PughDenver$15K
- Karyn GoodmanAurora$12K
- Jonathan ClarkDurango$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.